Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 1,261–1,280 of 17,937 drug recalls

Drug Recall Ongoing Historical recordClass I

Adrenalin Chloride Solution (Epinephrine Nasal Solution, USP), 30mg/30mL (1mg/mL), packaged in 30 mL vials, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-103-01

by ENDO USA, Inc.

Reason
Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)
Recall initiated
December 20, 2024
Reported by FDA
February 12, 2025
Distribution
USA nationwide.

View recall →

Drug Recall Terminated Historical recordClass III

Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc., Greenville, SC 29605, NDC 0121-0775-16

by PAI Holdings, LLC. dba Pharmaceutical Associates Inc

Reason
Superpotent; sodium benzoate preservative
Recall initiated
January 7, 2025
Reported by FDA
February 12, 2025
Distribution
OH

View recall →

Drug Recall Ongoing Historical recordClass II

Potassium Chloride Extended-Release Tablets, USP, 10 mEq (750 mg), 100 Tablets per carton (10 x 10 unit dose blisters), Rx Only, Distributed by: Aurobindo Pharma USA< INC., 279 Princeton-Hightstown Road, East Windsor, NJ 08520. Made in India. Distributed by: MAJOR PHARMACEUTICALS, Livonia, MI 48152. NDC: 0904-7216-61

by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories

Reason
Failed Dissolution Specifications.
Recall initiated
January 30, 2025
Reported by FDA
February 12, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

HydrALAZINE Hydrochloride, 100 Tablets (10x10), USP, 50mg, Rx only, Manufactured by Strides Pharma Science Ltd, Bengaluru, India, Distributed by McKesson by: McKesson Corporation dba SKY Packaging, TN 38141. NDC 63739-328-10

by SKY PACKAGING

Reason
Failed Impurities/Degradation Specifications
Recall initiated
January 24, 2025
Reported by FDA
February 12, 2025
Distribution
Nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass II

HydrALAZINE Hydrochloride, 25 mg, 100 Unit Dose Tablets (10x10), USP, Rx only, Manufactured by Strides Pharma Science Ltd, Bengaluru, India, Distributed by McKesson by: McKesson Corporation dba SKY Packaging, TN 38141. NDC 63739-327-10

by SKY PACKAGING

Reason
Failed Impurities/Degradation Specifications
Recall initiated
January 24, 2025
Reported by FDA
February 12, 2025
Distribution
Nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass II

Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel.

by Teva Pharmaceuticals USA, Inc

Reason
Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
Recall initiated
January 10, 2025
Reported by FDA
February 12, 2025
Distribution
Product was distributed nationwide.

View recall →

Drug Recall Terminated Historical recordClass II

Carvedilol 25 mg Tablet, QTY: 30 Tablets per Blister Pack (3 x 10 blister cards), Rx Only, MFG by: Glenmark, Mahwah, NJ 07430, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC: 70518-3945-00.

by RemedyRePack Inc.

Reason
CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.
Recall initiated
January 24, 2025
Reported by FDA
February 12, 2025
Distribution
FL

View recall →

Drug Recall Ongoing Historical recordClass II

Carvedilol Tablets, USP, 12.5 mg, Rx only, a)500 Tablets, NDC 68462-164-05; b) 100 Tablets, NDC 68462-164-01, Manufactured for Glenmark Pharmaceuticals, NJ.

by Glenmark Pharmaceuticals Inc., USA

Reason
CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
Recall initiated
January 22, 2025
Reported by FDA
February 12, 2025
Distribution
Nationwide in the U.S

View recall →

Drug Recall Ongoing Historical recordClass II

Carvedilol Tablets, USP, 25 mg, Rx only, a)500 Tablets, NDC 68462-165-05; b) 100 Tablets, NDC 68462-165-01, Manufactured for Glenmark Pharmaceuticals, NJ.

by Glenmark Pharmaceuticals Inc., USA

Reason
CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
Recall initiated
January 22, 2025
Reported by FDA
February 12, 2025
Distribution
Nationwide in the U.S

View recall →

Drug Recall Ongoing Historical recordClass II

Timolol Maleate Ophthalmic Solution USP, 0.5%, Sterile, 5mL bottles, Rx only, Manufactured by: FDC Limited, Waluj, Aurangabad, Maharashtra, India, Distributed by: Rising Pharmaceuticals Inc, New Jersey, NDC 64980-514-05.

by FDC Limited

Reason
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Recall initiated
January 23, 2025
Reported by FDA
February 12, 2025
Distribution
Distributed to one (1) Us Distributor in NJ

View recall →

Drug Recall Ongoing Historical recordClass II

Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01

by McKesson

Reason
cGMP Deviations: Product intended for quarantine was inadvertently distributed.
Recall initiated
January 17, 2025
Reported by FDA
February 5, 2025
Distribution
Nationwide USA

View recall →

Drug Recall Terminated Historical recordClass II

Duloxetine Delayed-Release Capsules USP, 20 mg, packaged in a) 30 Unit Doses (3x10 blister packs) NDC 0904-7043-04 and b) 100 Unit Doses (10x10 blister packs) NDC 0904-7043-61, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA.

by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories

Reason
CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit
Recall initiated
January 13, 2025
Reported by FDA
February 5, 2025
Distribution
Nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass I

Prograf (tacrolimus) capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Product of Japan, Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062, NDC 0469-0607-73.

by Astellas Pharma US Inc.

Reason
Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
Recall initiated
December 23, 2024
Reported by FDA
February 5, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass I

Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73.

by Astellas Pharma US Inc.

Reason
Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
Recall initiated
December 23, 2024
Reported by FDA
February 5, 2025
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass III

BADGER 50, ADVENTURE SPORT MINERAL SUNSCREEN WITH CLEAR ZINC, (uncoated 25% zinc oxide), 2.4 oz., Tin, W.S. Badger Company, Inc, 768 Route 10, Gilsum NH, 03448 UPC 6 34084 47150 2

by The W.S. Badger Company, Inc.

Reason
Labeling: Missing Label: The finished product potentially missing the labeling with the drug facts panel, bar code and directions for use.
Recall initiated
January 17, 2025
Reported by FDA
February 5, 2025
Distribution
Distributed Nationwide in the USA

View recall →

Drug Recall Completed Historical recordClass III

Venlafaxine Extended-Release Tablets, 150mg, Rx only, 90 Tablets, Manufactured by Appco Pharma. LLC, NDC 43598-943-90.

by Appco Pharma LLC

Reason
Failed Tablet/Capsule Specifications: Missing tab ID on either side of the tablet
Recall initiated
January 16, 2025
Reported by FDA
January 29, 2025
Distribution
Nationwide USA.

View recall →

Drug Recall Ongoing Historical recordClass I

FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and Distributed by Shoppers-Plaza, Hawthorne, CA 90250. Product of India. UPC 8 26656 69047 7

by SHOPPERS- PLAZA

Reason
Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide
Recall initiated
December 16, 2024
Reported by FDA
January 29, 2025
Distribution
Nationwide via internet sales

View recall →

Drug Recall Ongoing Historical recordClass II

First Aid Beauty Ultra Repair Cream, colloidal oatmeal 0.5%, Coconut Vanilla, Net Wt. 396.8 g (14 OZ), DISTR. BY: First Aid Beauty LTD, Newton, MA, 02458, UPC 8 15517 02955 6

by First Aid Beauty Ltd

Reason
CGMP Deviations; product intended for quarantine was inadvertently distributed
Recall initiated
December 23, 2024
Reported by FDA
January 29, 2025
Distribution
Nationwide

View recall →

Drug Recall Ongoing Historical recordClass II

Kissable Diabetics Foot Cream, NET WT 4 oz (113 g) per tube, Manufactured By: Brands International Corp., Newmarket, ON, L3X 2S2. UPC 6 72008 80925 3

by Brands International Corporation

Reason
CGMP Deviations: lack of adequate release testing.
Recall initiated
November 13, 2024
Reported by FDA
January 29, 2025
Distribution
Nationwide USA

View recall →

Drug Recall Terminated Historical recordClass II

Cardura XL (doxazosin) extended release tablets 4 mg, 30 -count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-078-93

by Viatris Inc

Reason
Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
Recall initiated
December 23, 2024
Reported by FDA
January 22, 2025
Distribution
USA nationwide.

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.